Atypical Hemolytic Uremic Syndrome in a 13-year-old Lao Girl: A Case Report
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombotic microangiopathy, is distinguished from the typical form by the absence of a preceding verotoxin-producing Escherichia coli infection. Notably, aHUS occurs in association with genetic or acquired disorders causing dysregulation of the alternative complement pathway. Patients with aHUS may show the presence of anti-complement factor H (CFH) autoantibodies. This acquired form of aHUS (anti- CFH-aHUS) primarily affects children aged 9–13 years. We report a case of a 13-year-old Lao girl with clinical features of aHUS (most likely anti-CFH-aHUS). The initial presentation of the patient met the classical clinical triad of thrombotic microangiopathy (microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury) without preceding diarrheal illness. Low serum levels of complement 3 and normal levels of complement 4 indicated abnormal activation of the alternative complement pathway. Plasma infusion and high-dose corticosteroid therapy resulted in improvement of the renal function and hematological profile, although the patient subsequently died of infectious complications. This is the first case report that describes aHUS (possibly anti-CFHaHUS) in Laos.
Abstract
Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombotic microangiopathy, is distinguished from the typical form by the absence of a preceding verotoxin-producing Escherichia coli infection. Notably, aHUS occurs in association with genetic or acquired disorders causing dysregulation of the alternative complement pathway. Patients with aHUS may show the presence of anti-complement factor H (CFH) autoantibodies. This acquired form of aHUS (anti- CFH-aHUS) primarily affects children aged 9–13 years. We report a case of a 13-year-old Lao girl with clinical features of aHUS (most likely anti-CFH-aHUS). The initial presentation of the patient met the classical clinical triad of thrombotic microangiopathy (microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury) without preceding diarrheal illness. Low serum levels of complement 3 and normal levels of complement 4 indicated abnormal activation of the alternative complement pathway. Plasma infusion and high-dose corticosteroid therapy resulted in improvement of the renal function and hematological profile, although the patient subsequently died of infectious complications. This is the first case report that describes aHUS (possibly anti-CFHaHUS) in Laos.
참고문헌 (15)
- Noris M, "Atypical hemolytic-uremic syndrome", N Engl J Med, 361, pp.1676~1687 (2009)
- Lee JM, "Atypical hemolytic uremic syndrome : Korean pediatric series", Pediatr Int, 57, pp.431~438 (2015)
- Fremeaux-Bacchi V, "Genetics and outcome of atypical hemolytic uremic syndrome : A nationwide French series comparing children and adults", Clin J Am Soc Nephrol, 8, pp.554~562 (2013)
- ragon-Durey MA, "Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome", J Am Soc Nephrol, 16, pp.555~563 (2005)
- Lee BH, "Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1", CFHR3 deficiency, 2009, pp.66, 336~340
- Dragon-Durey MA, "Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome", J Am Soc Nephrol, 21, pp.2180~2187 (2010)
- chaefer F, "Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome", Kidney Int, 94, pp.408~418 (2018)
- Sellier-Leclerc AL, "Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome", J Am Soc Nephrol, 18, pp.2392~2400 (2007)
- inha A, "Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children", Kidney Int, 85, pp.1151~1160 (2014)
- Hofer J, "Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome", Clin J Am Soc Nephrol, 8, pp.407~415 (2013)
- Brocklebank V, "Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland", Kidney Int, 92, pp.1261~1271 (2017)
- Jozsi M, "Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1", CFHR3 deficiency, 2008, pp.111, 1512~1514
- Khandelwal P, "Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome", Pediatr Nephrol, 30, pp.451~457 (2015)
- Hisano M, "Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy", Pediatr Int, 57, pp.313~317 (2015)
- Ito N, "Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan", Clin Exp Nephrol, 20, pp.265~272 (2015)